← Back to Search

Alkylating agents

Paclitaxel + Carboplatin for Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 years post treatment
Awards & highlights

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor to plan treatment may result in more effective radiation therapy. It is not yet known which chemotherapy and/or radiation therapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens and 3-dimensional radiation therapy in treating patients who have unresectable stage III non-small cell lung cancer.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 years post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response
Secondary outcome measures
Overall Survival
Toxicity

Trial Design

2Treatment groups
Experimental Treatment
Group I: Paclitaxel + CarboplatinExperimental Treatment3 Interventions
Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
Group II: Gemcitabine + CarboplatinExperimental Treatment3 Interventions
Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
radiation therapy
1994
Completed Phase 3
~13390
Paclitaxel
FDA approved
Carboplatin
FDA approved
Gemcitabine
FDA approved

Find a Location

Who is running the clinical trial?

Alliance for Clinical Trials in OncologyLead Sponsor
512 Previous Clinical Trials
217,557 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,332 Total Patients Enrolled
Arthur William Blackstock, MDStudy ChairWake Forest University Health Sciences
7 Previous Clinical Trials
680 Total Patients Enrolled
~3 spots leftby Jun 2025